ZA982253B - Therapeutic compositions. - Google Patents

Therapeutic compositions.

Info

Publication number
ZA982253B
ZA982253B ZA9802253A ZA982253A ZA982253B ZA 982253 B ZA982253 B ZA 982253B ZA 9802253 A ZA9802253 A ZA 9802253A ZA 982253 A ZA982253 A ZA 982253A ZA 982253 B ZA982253 B ZA 982253B
Authority
ZA
South Africa
Prior art keywords
therapeutic compositions
therapeutic
compositions
Prior art date
Application number
ZA9802253A
Other languages
English (en)
Inventor
Richard Lewis Veech
Original Assignee
British Tech Group
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Tech Group filed Critical British Tech Group
Publication of ZA982253B publication Critical patent/ZA982253B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Biological Depolymerization Polymers (AREA)
ZA9802253A 1997-03-17 1998-03-17 Therapeutic compositions. ZA982253B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4085897P 1997-03-17 1997-03-17

Publications (1)

Publication Number Publication Date
ZA982253B true ZA982253B (en) 1999-09-17

Family

ID=21913362

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9802253A ZA982253B (en) 1997-03-17 1998-03-17 Therapeutic compositions.

Country Status (11)

Country Link
EP (2) EP2283834B1 (xx)
JP (3) JP4740426B2 (xx)
KR (1) KR100839689B1 (xx)
CN (2) CN1552315B (xx)
AU (2) AU749638B2 (xx)
CA (1) CA2283642C (xx)
DK (2) DK1017379T3 (xx)
ES (1) ES2530753T3 (xx)
RU (1) RU2224510C2 (xx)
WO (2) WO1998041200A1 (xx)
ZA (1) ZA982253B (xx)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323237B1 (en) 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
US6316038B1 (en) 1997-03-17 2001-11-13 Btg International Limited Therapeutic compositions
EP1098655B1 (en) 1998-07-22 2004-11-24 Metabolix, Inc. Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers
CN1273129C (zh) * 1998-09-15 2006-09-06 英国技术集团国际有限公司 治疗组合物(ⅱ)
ES2323940T3 (es) * 2000-05-01 2009-07-28 Accera, Inc. Uso de trigliceridos de cadena media para el tratamiento y prevencion de la enfermedad de alzheimer.
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
AU2001291173A1 (en) * 2000-09-22 2002-04-02 Orphan Medical, Inc. Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
ES2670413T3 (es) 2003-06-03 2018-05-30 The United States Government As Represented By The Department Of Health And Human Services Suplementos nutricionales y composiciones terapéuticas que comprenden derivados de (R)-3-hidroxibutirato
WO2005021013A1 (ja) * 2003-09-01 2005-03-10 Earthus, Inc. β−ヒドロキシ短〜中鎖脂肪酸重合体
GB0410266D0 (en) * 2004-05-07 2004-06-09 Ketocytonyx Inc Treatment of apoptosis
GB0420856D0 (en) * 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
EP1778615A4 (en) 2004-07-20 2010-01-06 Btg Int Ltd OLIGOMERE KETONE COMPOUNDS
US20060252775A1 (en) * 2005-05-03 2006-11-09 Henderson Samuel T Methods for reducing levels of disease associated proteins
EP1915144A4 (en) 2005-06-20 2009-08-19 Accera Inc METHOD FOR REDUCING OXIDATIVE DAMAGE AND IMPROVING MITOCHONDRIA EFFICIENCY
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
BRPI0619905A2 (pt) * 2005-12-15 2011-10-25 Nestec Sa composições e métodos para conservar função cerebral
EP2500017B1 (en) * 2006-04-03 2017-09-06 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
JP5030553B2 (ja) * 2006-11-24 2012-09-19 有限会社ノーベル医学研究所 ドライマウスおよび／または唾液分泌障害を処置するための医薬
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
WO2008120778A1 (ja) * 2007-03-30 2008-10-09 Earthus, Inc. ケトン体生成促進剤組成物
BRPI0811052A2 (pt) 2007-04-12 2015-01-27 Univ Minnesota Composições de proteção de isquemia/reperfusão e métodos de uso.
PT2650380E (pt) 2007-07-31 2016-01-14 Accera Inc Utilização de testagem genómica e compostos cetogénicos para o tratamento de função cognitiva reduzida
CN101969769A (zh) * 2008-01-04 2011-02-09 伊希斯创新有限公司 用作降低血脂药剂的酮体和酮体酯
JP5630750B2 (ja) * 2008-03-18 2014-11-26 国立大学法人 岡山大学 興奮性化学伝達調節剤およびそのスクリーニング法
CA2729622C (en) 2008-07-03 2017-07-25 Accera, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
US8105809B2 (en) 2008-07-03 2012-01-31 Accera, Inc. Enzymatic synthesis of acetoacetate esters and derivatives
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
EP2389182A1 (en) 2009-01-24 2011-11-30 Phytopharm PLC Treatment of neurotrophic factor mediated disorders
US8461197B2 (en) 2009-04-23 2013-06-11 Concert Pharmaceuticals, Inc. 4-hydroxybutyric acid analogs
US20110118528A1 (en) * 2009-10-22 2011-05-19 University Of Southern California Methods and Nutritional Formulations to Increase the Efficacy and Reduce the Side Effects of Cancer Treatment
GB201002983D0 (en) * 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
US20130210786A1 (en) 2010-07-20 2013-08-15 Patrick Alexander Howson Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
MX355742B (es) 2011-02-14 2018-04-26 Concert Pharmaceuticals Inc Análogos deuterados del ácido 4-hidroxibutírico.
WO2013007003A1 (zh) * 2011-07-08 2013-01-17 中国医学科学院基础医学研究所 乙酰乙酸调节骨骼肌细胞增殖的新用途
JP6883384B2 (ja) 2012-11-05 2021-06-09 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 電離放射線による傷害から組織を防護するためのケトン体
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
GB2515603B (en) 2013-03-14 2015-10-14 Isis Innovation Process for producing (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate
KR20150130312A (ko) 2013-03-19 2015-11-23 유니버시티 오브 사우스 플로리다 상승되고 지속되는 케톤증을 생성하기 위한 조성물 및 방법
DE102013012494A1 (de) * 2013-07-26 2015-01-29 Irma Baumeister Verwendung von ß-Hydroxybuttersäure und Acetessigsäure sowie ihrer Salze (ß-Hydroxybutyrat und Acetacetat) als Mittel zur Behandlung bei erworbener Hypoglycorrhachie in Folge von Meningitis, Encephalitis oder Blutung in die Liquorräume
GB201314127D0 (en) * 2013-08-07 2013-09-18 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown
WO2016012657A1 (en) * 2014-07-21 2016-01-28 Oulun Yliopisto Oligomeric forms of 3-hydroxybutyrate
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US10245243B1 (en) 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
JP6710098B2 (ja) * 2016-05-10 2020-06-17 大阪瓦斯株式会社 栄養剤組成物及び栄養補助食品
CN114292190A (zh) * 2016-06-07 2022-04-08 J大卫格莱斯顿研究机构 丁二醇的中链脂肪酸酯，其组合物、口服制剂及其应用方法
US10307398B2 (en) 2016-09-20 2019-06-04 Regents Of The University Of Minnesota Resuscitation composition and methods of making and using
CA3046415A1 (en) * 2016-12-21 2018-06-28 Universitats-Kinderspital Beider Basel Migraine prevention and treatment
US9925164B1 (en) 2017-01-12 2018-03-27 Neuroenergy Ventures, Inc. Glyceryl 3-hydroxybutyrates for traumatic brain injury
CA3053663C (en) * 2017-04-12 2021-09-07 Franco CAVALERI Butyrate and beta-hydroxybutyrate compositions and methods of use thereof
GB201710229D0 (en) * 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use
BR112020001285A2 (pt) 2017-07-21 2020-07-28 Buck Institute For Research On Aging s-enantiômeros de beta-hidroxibutirato e butanodiol e métodos para sua utilização
CN111050779A (zh) * 2017-08-18 2020-04-21 佐藤拓己 血糖值尖峰抑制剂、食品及血糖值尖峰抑制剂的制造方法
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10925843B2 (en) * 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
WO2019147503A1 (en) 2018-01-25 2019-08-01 Buck Institute For Research On Aging Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US10512615B1 (en) 2018-08-27 2019-12-24 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
EP3801496A4 (en) * 2018-06-05 2022-07-06 Flagship Pioneering Innovations V, Inc. ACTIVE AGENTS AND METHODS OF USE THEREOF FOR TREATING METABOLIC DISORDERS AND NAFLD
US20220257546A1 (en) * 2019-05-10 2022-08-18 Ketoswiss Ag Ketone bodies enclosed in microbeads
EP3975754A1 (en) * 2019-05-28 2022-04-06 Mayo Foundation for Medical Education and Research Nutritional health supplements
CN113710243A (zh) * 2019-05-30 2021-11-26 神经活力投资公司 甘油三(β-羟基丁酸酯)与神经元短暂性脑缺血发作
WO2020249197A1 (de) * 2019-06-12 2020-12-17 Ioi Oleo Gmbh Verfahren zur herstellung von acylverkappten 3-hydroxycarbonsäuren sowie deren salzen und estern
WO2020249198A1 (de) * 2019-06-12 2020-12-17 Ioi Oleo Gmbh Verfahren zur herstellung von polyolbasierten estern von acylverkappten 3-hydroxycarbonsäuren
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
CN110776425B (zh) * 2019-10-23 2021-02-26 清华大学 一种(r)-3-羟基丁酸及其低聚物的制备方法
JP7507580B2 (ja) * 2020-03-25 2024-06-28 大阪瓦斯株式会社 醸造酢代替物の製造方法、醸造酢代替物および醸造酢代替物含有食品
JP2021185799A (ja) * 2020-05-28 2021-12-13 大阪瓦斯株式会社 ３−ヒドロキシ酪酸含有油脂組成物
CN113200849A (zh) * 2021-04-27 2021-08-03 香港理工大学 合成的3-羟基丁酸酯低聚物或寡聚物的分离纯化方法及其在抗菌抗病毒制品中的应用
CN113866399A (zh) * 2021-11-03 2021-12-31 上海交通大学医学院附属仁济医院 肝脏酮体在急性胰腺炎病情监测和治疗上的应用
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
CN117243939A (zh) * 2023-11-14 2023-12-19 南京今冉生物新材料科技有限公司 一种酮体缓释物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1912406A1 (de) * 1969-03-12 1970-10-01 Basf Ag Verfahren zur Herstellung von Acetessigsaeureestern
CH626651A5 (xx) * 1976-08-06 1981-11-30 Agroferm Ag
JPS54138126A (en) * 1978-04-17 1979-10-26 Ajinomoto Co Inc Remedy for diabetes
IT1206954B (it) * 1979-02-12 1989-05-17 Sigma Tau Ind Farmaceuti Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
DE2930405C2 (de) * 1979-07-26 1982-09-23 Optische Werke G. Rodenstock, 8000 München Stimulus-Leuchte für augenoptische Untersuchungsgertäte
FR2521857B1 (fr) * 1982-02-23 1985-10-31 Solvay Compositions pharmaceutiques contenant de l'acide 3-hydroxybutanoique ou un sel derive de cet acide et sels derives de l'acide 3-hydroxybutanoique et d'une base organique azotee
GB2126082A (en) * 1982-08-12 1984-03-21 Heinrich Schulze Pharmaceutical preparations having analgetic and cytostatic activity
US5719119A (en) * 1985-12-18 1998-02-17 British Technology Group, Ltd. Parenteral nutrition therapy with amino acids
AU6777487A (en) * 1985-12-18 1987-07-15 Veech, R.L. Parenteral nutrition therapy with amino acids
BE1001209A3 (fr) * 1987-11-19 1989-08-22 Solvay Compositions pharmaceutiques contenant un derive de l'acide 3-hydroxybutanoique choisi parmi les oligomeres de cet acide et les esters de cet acide ou de ces oligomeres avec du 1,3-butanediol.
US5126373A (en) * 1987-11-19 1992-06-30 Henri Brunengraber Composition for parenteral and oral nutrition
CA1334575C (en) * 1988-07-26 1995-02-28 Atsushi Hiraide Substitution fluid preparation comprising 3-hydroxybutyric acid (beta-hydroxybutyric acid) and its salts
US5116868A (en) * 1989-05-03 1992-05-26 The Johns Hopkins University Effective ophthalmic irrigation solution
IT1240775B (it) * 1990-02-23 1993-12-17 Sigma Tau Ind Farmaceuti Esteri della l-carnitina e di acil-l-carnitine con l'acido beta-idrossibutirrico e composizioni farmaceutiche che li contengono per la inibizione della degenerazione neuronale, della proteolisi epatica e nel trattamento del coma.
JPH0733653A (ja) * 1993-06-25 1995-02-03 Suntory Ltd アセトアルデヒド毒性の抑制剤
WO1995009145A1 (en) * 1993-09-30 1995-04-06 Eastman Chemical Company NUTRITIVE GLYCEROL ESTERS OF β-ACYLOXY BUTYRATES
JP4598203B2 (ja) 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
JPH10120553A (ja) * 1996-10-23 1998-05-12 Eisai Co Ltd 抗痴呆薬含有製剤

Also Published As

Publication number Publication date
AU6513298A (en) 1998-10-12
RU2224510C2 (ru) 2004-02-27
ES2530753T3 (es) 2015-03-05
CN1315473C (zh) 2007-05-16
JP5800453B2 (ja) 2015-10-28
JP2015042644A (ja) 2015-03-05
EP1017379B1 (en) 2014-12-10
CA2283642A1 (en) 1998-09-24
JP2009173677A (ja) 2009-08-06
AU6556998A (en) 1998-10-12
CN1552315A (zh) 2004-12-08
CN1552315B (zh) 2010-11-10
JP2001515510A (ja) 2001-09-18
DK1017379T3 (en) 2015-02-16
KR20000076379A (ko) 2000-12-26
JP4740426B2 (ja) 2011-08-03
CA2283642C (en) 2012-05-15
EP2283834A2 (en) 2011-02-16
EP2283834B1 (en) 2016-07-13
WO1998041201A1 (en) 1998-09-24
WO1998041200A1 (en) 1998-09-24
KR100839689B1 (ko) 2008-06-18
EP1017379A4 (en) 2007-01-24
DK2283834T3 (en) 2016-08-15
CN1256629A (zh) 2000-06-14
EP1017379A1 (en) 2000-07-12
EP2283834A3 (en) 2012-02-01
AU749638B2 (en) 2002-06-27

Similar Documents

Publication Publication Date Title
ZA982253B (en) Therapeutic compositions.
ZA984849B (en) Compositions.
ZA987844B (en) Therapeutic combinations.
ZA987839B (en) Combination therapy.
HK1027957A1 (en) Pharmaceutical composition.
ZA9711029B (en) Therapeutic agents.
ZA974735B (en) Pharmaceutical compositions.
HK1038884A1 (en) Medicinal compositions.
ZA987843B (en) Combination therapy.
GB9702238D0 (en) Compositions
ZA977104B (en) Pharmaceutical compositions.
ZA989680B (en) Pharmaceutical composition.
ZA987797B (en) Oral compositions.
HK1022853A1 (en) Pharmaceutical compositions.
ZA9811502B (en) Novel composition.
ZA987392B (en) Pharmaceutical composition.
ZA972602B (en) Pharmaceutical compositions.
GB9705989D0 (en) Therapeutic composition
ZA984696B (en) Vaccine compositions V.
ZA981739B (en) Composition.
GB9705340D0 (en) Compositions
GB9703109D0 (en) Compositions
GB9712981D0 (en) Compositions
ZA982367B (en) Pharmaceutical compositions.
GB2336368B (en) Compositions